TRPV1: A Potential Therapeutic Target in Type 2 Diabetes and Comorbidities?

被引：41
|
作者：
Gram, Dorte X. [1 ]
Holst, Jens J. [2 ]
Szallasi, Arpad [3 ]
机构：
[1] Pila Pharma, Malmo, Sweden
[2] Univ Copenhagen, Panum Inst, Copenhagen, Denmark
[3] Baptist Med Ctr, Jacksonville, FL USA
来源：
TRENDS IN MOLECULAR MEDICINE | 2017年 / 23卷 / 11期
关键词：
GENE-RELATED PEPTIDE; SENSORY NERVE DESENSITIZATION; SUBSTANCE-P; INSULIN-SECRETION; GLUCOSE-TOLERANCE; PERIPHERAL NEUROPATHY; INFLAMMATORY MARKERS; VANILLOID RECEPTOR-1; CAPSAICIN RECEPTORS; ISLET INFLAMMATION;
D O I：
10.1016/j.molmed.2017.09.005
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
With an estimated 422 million affected patients worldwide in 2016, type 2 diabetes (T2D) has reached pandemic proportions and represents a major unmet medical need. T2D is a polygenic disease with a chronic, low-grade inflammatory component. Second-generation transient receptor potential vanilloid-1 (TRPV1) antagonists are potent anti-inflammatory agents with proven clinical safety. In rodent models of T2D, TRPV1 blockade was shown to halt disease progression and improve glucose metabolism. Thus, we propose that TRPV1 antagonists merit further study as novel therapeutic approaches to potentially treat T2D and its comorbidities.
引用
收藏
页码：1002 / 1013
页数：12
相关论文
共 50 条
  • [41] Acute Versus Progressive Onset of Diabetes in NOD Mice: Potential Implications for Therapeutic Interventions in Type 1 Diabetes
    Mathews, Clayton E.
    Xue, Song
    Posgai, Amanda
    Lightfoot, Yaima L.
    Li, Xia
    Lin, Andrea
    Wasserfall, Clive
    Haller, Michael J.
    Schatz, Desmond
    Atkinson, Mark A.
    DIABETES, 2015, 64 (11) : 3885 - 3890
  • [42] Therapeutic potential of resveratrol in obesity and type 2 diabetes: new avenues for health benefits?
    Timmers, Silvie
    Hesselink, Matthijs K. C.
    Schrauwen, Patrick
    RESVERATROL AND HEALTH, 2013, 1290 : 83 - 89
  • [43] Expression of the transient receptor potential channels TRPV1, TRPA1 and TRPM8 in mouse trigeminal primary afferent neurons innervating the dura
    Huang, Dongyue
    Li, Shuyang
    Dhaka, Ajay
    Story, Gina M.
    Cao, Yu-Qing
    MOLECULAR PAIN, 2012, 8
  • [44] Therapeutic potential of vasoactive intestinal peptide and its receptor VPAC2 in type 2 diabetes
    Hou, Xintong
    Yang, Dan
    Yang, Guimei
    Li, Mengnan
    Zhang, Jian
    Zhang, Jiaxin
    Zhang, Yi
    Liu, Yunfeng
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [45] The potential therapeutic role of IL-35 in pathophysiological processes in type 1 diabetes mellitus
    Bakery, Heba H.
    Hussein, Heba A. A.
    Ahmed, Osama M.
    Abuelsaad, Abdelaziz S. A.
    Khalil, Rehab G.
    CYTOKINE, 2024, 182
  • [46] PYY, a Therapeutic Option for Type 2 Diabetes?
    Guida, Claudia
    Ramracheya, Reshma
    CLINICAL MEDICINE INSIGHTS-ENDOCRINOLOGY AND DIABETES, 2020, 13
  • [47] The Role and Potential Therapeutic Implications of the Fibroblast Growth Factors in Energy Balance and Type 2 Diabetes
    Izaguirre, Maitane
    Gil, Maria J.
    Monreal, Ignacio
    Montecucco, Fabrizio
    Fruhbeck, Gema
    Catalan, Victoria
    CURRENT DIABETES REPORTS, 2017, 17 (06)
  • [48] Different mechanisms of GIP and GLP-1 action explain their different therapeutic efficacy in type 2 diabetes
    Grespan, Eleonora
    Giorgino, Toni
    Natali, Andrea
    Ferrannini, Ele
    Mari, Andrea
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2021, 114
  • [49] Emerging Role of PACAP as a New Potential Therapeutic Target in Major Diabetes Complications
    Marzagalli, Rubina
    Scuderi, Soraya
    Drago, Filippo
    Waschek, James A.
    Castorina, Alessandro
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2015, 2015
  • [50] Synthesis and vasodilator effects of rutaecarpine analogues which might be involved transient receptor potential vanilloid subfamily, member 1 (TRPV1)
    Chen, Zhuo
    Hu, Gaoyun
    Li, Dai
    Chen, Jun
    Li, Yuanjian
    Zhou, Huayong
    Xie, Ye
    BIOORGANIC & MEDICINAL CHEMISTRY, 2009, 17 (06) : 2351 - 2359
12345